Results for Presenilin-1

Publications & Outputs

1. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

   McClean, P. L. & Holscher, C., 11/2014, In: Neuropharmacology. 86, p. 241-258 18 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

2. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease

   Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O'Halloran, D. J., Holscher, C. & O'Neill, C., 03/2013, In: NeuroMolecular Medicine. 15, 1, p. 102-114 13 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

3. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease

   Duffy, A. M. & Hölscher, C., 3/01/2013, In: Neuroscience. 228, p. 294-300 7 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

4. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease

   Hamilton, A. & Holscher, C., 17/04/2012, In: Brain Research. 1449, p. 83-93 11 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

5. Presenilins: in search of functionality

   Karran, E. H., Allsop, D., Christie, G., Davis, J., Gray, C., Mansfield, F. & Ward, R. V., 08/1998, In: Biochemical Society Transactions. 26, 3, p. 491-496 6 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review